Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced its results for the first quarter of FY-2015. The results shows EPS went stable at -$0.06 YoY, whereas Cash assets were reduced from $ 57.289 Million to $ 49.987 Million. View the full earnings release here.
Mast Therapeutics Losses Reduced $MSTX $XHS Read More »
BioDelivery Sciences International, Inc., has announced its financial results for the first quarter of FY-2015. The results shows Revenues down from $20.690 Million to $13.054 Million YoY, whereas EPS spreads from -$0.11 to -$0.16 YoY. View the full earnings release here.
BioDelivery Revenues Down $BDSI $XHS Read More »
Kindred Biosciences, Inc., has announced its results for the first quarter of FY-2015. The results shows EPS went improves from, -$0.38 to -$0.34 YoY, whereas cash and Equivalents also went down to $94.589 Million from $101.027 Million Quarterly. View the full earnings here.
Kindred Widens Losses $KIN $XHS Read More »
Endocyte, Inc., a bio pharmaceutical company, develops therapies for the treatment of cancer and inflammatory diseases, has announced its results for first quarter of FY-2015. The results shows, Revenues rise to $ 17,269,000 from $ 12,000, and EPS improves from -$0.26 to -$0.09 . View the full earnings release here.
Endocyte Revenues Rise $ECYT $XHS Read More »
Osiris Therapeutics, Inc., the leading wound care medicines, cellular and regenerative medicine firm, has announced first quarter 2015 financial results. The results shows revenue was $21.0 million Up by 109% YoY, while EPS also improved from -$0.02 to $0.04. View the full earnings release here.
Osiris Revenues Rise $OSIR $XHS Read More »
